Robert Norton

Dr. Robert Norton

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
PDF file
SDSamantha Dando
Samantha Dando
AMAlan Mackay-Sim
Alan Mackay-Sim
RNRobert Norton
Robert Norton
BCBart J. Currie
Bart J. Currie
James St JohnJames St John
James St John
IBIfor R. Beacham
Ifor R. Beacham
SUMMARY The brain is well protected against microbial invasion by cellular barriers, such as the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). In addition, cells within the central nervous system (CNS) are capable of producing an immune response against invading pathogens. Nonetheless, a range of pathogenic microbes make their way to the CNS, and the resulting infections can cause significant morbidity and mortality. Bacteria, amoebae, fungi, and viruses are capable of CNS invasion, with the latter using axonal transport as a common route of infection. In this review, we compare the mechanisms by which bacterial pathogens reach the CNS and infect the brain. In particular, we focus on recent data regarding mechanisms of bacterial translocation from the nasal mucosa to the brain, which represents a little explored pathway of bacterial invasion but has been proposed as being particularly important in explaining how infection with Burkholderia pseudomallei can result in melioidosis encephalomyelitis.

18 March 2020 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
IGIan Gassiep
Ian Gassiep
MAM. Armstrong
M. Armstrong
RNRobert Norton
Robert Norton
The causative agent of melioidosis,Burkholderia pseudomallei, a tier 1 select agent, is endemic in Southeast Asia and northern Australia, with increased incidence associated with high levels of rainfall. Increasing reports of this condition have occurred worldwide, with estimates of up to 165,000 cases and 89,000 deaths per year. The ecological niche of the organism has yet to be clearly defined, although the organism is associated with soil and water. The culture of appropriate clinical material remains the mainstay of laboratory diagnosis.

20 September 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
FSFerris Satyaputra
Ferris Satyaputra
SHStephanie Hendry
Stephanie Hendry
MBMaxwell Braddick
Maxwell Braddick
PSPirathaban Sivabalan
Pirathaban Sivabalan
RNRobert Norton
Robert Norton
Syphilis is a multisystem infection caused by the spirochaete Treponema pallidum. Currently, cases of possible syphilis are commonly investigated using the treponemal serological tests T. pallidum IgG chemiluminescence immunoassay (CLIA) and the T. pallidum particle agglutination (TPPA). The non-treponemal rapid plasma reagin (RPR) flocculation test is used to assess disease activity. There has been a resurgence of syphilis diagnoses in Australia. Large foci of infection have been identified in isolated communities. The remoteness of these locations, in conjunction with the particular socio-cultural characteristics of the population, pose unique challenges to the traditional diagnostic and treatment paradigms for syphilis. As a consequence of this increased incidence of syphilis, there has been interest in the utility of point of care tests (POCT), nucleic acid amplification tests (NAAT), the role of IgM testing in suspected congenital syphilis, and the laboratory investigation of possible neurosyphilis. This review looks at the current status of traditional serological assays and provides an update on more recent methods. It assesses the published literature in this area and makes recommendations for the rational use of pathology testing to aid in the diagnosis of the many facets of syphilis.

1 December 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
RLRebecca Lipsitz
Rebecca Lipsitz
SGSusan Garges
Susan Garges
RARosemarie Aurigemma
Rosemarie Aurigemma
PBPrasith Baccam
Prasith Baccam
DBDavid D. Blaney
David D. Blaney
TSTheresa L. Smith
Theresa L. Smith
The US Public Health Emergency Medical Countermeasures Enterprise convened subject matter experts at the 2010 HHS Burkholderia Workshop to develop consensus recommendations for postexposure prophylaxis against and treatment for Burkholderia pseudomallei and B. mallei infections, which cause melioidosis and glanders, respectively. Drugs recommended by consensus of the participants are ceftazidime or meropenem for initial intensive therapy, and trimethoprim/sulfamethoxazole or amoxicillin/clavulanic acid for eradication therapy. For postexposure prophylaxis, recommended drugs are trimethoprim/sulfamethoxazole or co-amoxiclav. To improve the timely diagnosis of melioidosis and glanders, further development and wide distribution of rapid diagnostic assays were also recommended. Standardized animal models and B. pseudomallei strains are needed for further development of therapeutic options. Training for laboratory technicians and physicians would facilitate better diagnosis and treatment options.

1 February 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
AHAlex R. Hoffmaster
Alex R. Hoffmaster
DADavid AuCoin
David AuCoin
PBPrasith Baccam
Prasith Baccam
HBHenry C. Baggett
Henry C. Baggett
RBRobert Baird
Robert Baird
HWHenry T. Walke
Henry T. Walke
Melioidosis is a severe disease that can be difficult to diagnose because of its diverse clinical manifestations and a lack of adequate diagnostic capabilities for suspected cases. There is broad interest in improving detection and diagnosis of this disease not only in melioidosis-endemic regions but also outside these regions because melioidosis may be underreported and poses a potential bioterrorism challenge for public health authorities. Therefore, a workshop of academic, government, and private sector personnel from around the world was convened to discuss the current state of melioidosis diagnostics, diagnostic needs, and future directions.

1 December 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
PLPeter Lowe
Peter Lowe
CECatherine Engler
Catherine Engler
RNRobert Norton
Robert Norton
The identification of Burkholderia pseudomallei , the causative agent of melioidosis, is usually not difficult in laboratories in areas where it is endemic. With the increase in international travel and the threat of bioterrorism, it has become more likely that laboratories in areas where it is not endemic could encounter this organism. The increase in the use of and dependence upon automated identification systems makes accurate identification of uncommonly encountered organisms such as B. pseudomallei critically important. This study compares the manual API 20NE and 20E identification systems with the automated Vitek 1 and 2 systems. A total of 103 B. pseudomallei isolates were tested and correctly identified in 98%, 99%, 99%, and 19% of cases, respectively. The failure of the Vitek 2 to correctly identify B. pseudomallei was largely due to differences in the biochemical reactions achieved compared to expected values in the database. It is suggested that this deficiency in the Vitek 2 may be due to the large number of uncertain results reported for these isolates. These results reduce the discriminating ability of the instrument to distinguish between uncommonly encountered isolates such as those of B. pseudomallei .